InspireMD Announces Proposed Public Offering

Rhea-AI Summary

InspireMD (NSPR) has commenced a proposed public offering of common stock, pre-funded warrants and accompanying common warrants to purchase equity securities.

Pre-funded warrants would be offered instead of common stock to certain investors. InspireMD intends to grant underwriters a 30-day option for additional securities representing 15% of the common shares and pre-funded warrants sold, solely to cover over-allotments. The offering is subject to market and other conditions; its completion, timing, size and terms remain uncertain. Lake Street Capital Markets is the sole book runner. The company intends to use any net proceeds for research and development, sales and marketing, working capital and other general corporate purposes.

1 point · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed public offering would raise capital for InspireMD if completed.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed common shares, pre-funded warrants and accompanying common warrants would dilute holders through issuance or exercise.
• Minor point. Forward-looking: it has not happened yet and may not happen.Planned 30-day over-allotment option would permit additional securities representing 15% of common shares and pre-funded warrants sold.
• Minor pointOffering completion remains subject to market and other conditions, with timing, size and terms uncertain.

News Explained

InspireMD’s proposed offering has commenced but is not complete; pre-funded warrants are sold at nearly the full share price with a nominal exercise price and convert into shares when exercised, so issuing shares, including on exercise, can reduce existing holders’ percentage ownership, absent offsetting changes.

Argus 15 min delay 27 alerts

+4.50% vs previous close $0.8088 last price 1.8x rel. volume Open Argus

Details

Market move: NSPR +4.50% vs previous close. proposed public offering

$0.66 – $0.97 Day Range

$37.88M Mkt Cap at Last Price

On Nov 12, the day this news came out, the latest delayed price for NSPR is 4.50% above the previous close. Our momentum scanner has recorded 27 alerts for this stock so far that day. The latest delayed price is $0.81. Relative volume is above average at 1.8x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Underwriters' option: 30 days Over-allotment option size: 15%

Underwriters' option

30 days

Proposed option to purchase additional securities for over-allotments

Over-allotment option size

15%

Proposed option, measured against shares and pre-funded warrants sold in the offering

Key Terms

pre-funded warrants, over-allotments, shelf registration statement, form s-3

4 terms

pre-funded warrants financial

"pre-funded warrants to purchase shares of its common stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

over-allotments financial

"solely to cover over-allotments, if any"

An over-allotment is a temporary extra batch of shares that the underwriters of a stock offering are allowed to sell beyond the original amount, with the right to buy those shares back later. Think of it as spare tickets sold to meet demand and then reclaimed if needed to keep the market orderly; it helps stabilize the stock price after an offering and can affect short-term supply and potential dilution, which matters to investors tracking price and ownership stakes.

shelf registration statement regulatory

"pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"an effective shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard^® Prime carotid stent system for the prevention of stroke, today announced that it has commenced a proposed public offering of (i) shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, and (iii) accompanying common warrants to purchase shares of its common stock or pre-funded warrants in lieu thereof to purchase shares of its common stock. All securities in the proposed offering are being offered by InspireMD.

In addition, the Company intends to grant the underwriters a 30-day option to purchase additional shares of the Company’s common stock and/or pre-funded warrants and/or additional common stock warrants to purchase shares of common stock or pre-funded warrants in lieu thereof to purchase shares of its common stock (or any combination thereof), representing 15% of the total number of shares of common stock and pre-funded warrants sold in the offering, solely to cover over-allotments, if any.

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Lake Street Capital Markets is acting as the sole book runner for the proposed offering.

InspireMD intends to use the net proceeds from the proposed offering, if any, for research and development, sales and marketing, working capital and other general corporate purposes.

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-286309) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2025, and declared effective by the SEC on April 10, 2025. A preliminary prospectus supplement and accompanying base prospectus relating to the proposed offering will be filed with the SEC and, when available, may be obtained free of charge at www.sec.gov.  When available, copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering may be obtained from Lake Street Capital Markets, LLC at 121 South Eighth Street, Suite 1000, Minneapolis, MN 55402, or e-mail at prospectus@lakestreetcm.com. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

Forward-looking Statements

This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words.

In particular, forward-looking statements in this press release include the Company’s expectations regarding the proposed public offering, including its anticipated timing, size, terms and completion, and the intended use of proceeds from the offering. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.

Such risks and uncertainties include, without limitation, risks associated with the proposed public offering, including market conditions, the possibility that the offering may not be completed on the anticipated terms or at all, and the Company’s ability to deploy any proceeds from the offering as intended; risks and uncertainties associated with the voluntary U.S. recall of the CGuard Prime 135 cm delivery system, including current and future costs associated with the recall, including refunds or inventory write-off costs and other remediation costs, loss of sales and customers due to the recall or otherwise, our ability to effectively implement enhancements to CGuard Prime 135 cm delivery system, potential actions by regulators or other governmental entities associated with the recall, potential claims and lawsuits by customers and patients, including class action product liability lawsuits, other operational impacts and consequences of the recall, such as business disruption and distraction of management and other key employees; the Company’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s need to raise additional capital to meet its business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders’ ownership interests; the clinical development, commercialization and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than it does; entry of new competitors and products and potential technological obsolescence of the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and economic instability in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on the Company, its customers and suppliers, and the global economic environment.

More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contact

Investor Contacts:

Jeff Warren

LifeSci Advisors

jwarren@lifesciadvisors.com

investor-relations@inspiremd.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What securities is InspireMD (NSPR) proposing to offer?

InspireMD is proposing to offer common stock, pre-funded warrants instead of common stock to certain investors, and accompanying common warrants. The common warrants would purchase common stock or pre-funded warrants in lieu thereof. All securities are being offered by InspireMD.